Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Пролонгированная блокада ангиогенеза при метастатическом колоректальном раке (новые данные)
Пролонгированная блокада ангиогенеза при метастатическом колоректальном раке (новые данные)
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В представленном обзоре обсуждается новая стратегия пролонгированного применения бевацизумаба при метастатическом колоректальном раке. Анализ представленных рандомизированных исследований показал, что после инициального назначения препарата одновременно с более интенсивным химиотерапевтическим режимом целесообразно переходить на поддерживающее лечение бевацизумабом ± фторпиримидин. Введение бевацизумаба необходимо продолжать до прогрессирования болезни. При прогрессировании процесса продолжение бевацизумаба со сменой режима химиотерапии достоверно увеличивает показатели выживаемости и имеет преимущества перед другими терапевтическими опциями.
Ключевые слова: метастатический колоректальный рак, бевацизумаб, терапия после прогрессирования.
Key words: metastatic colorectal cancer, bevacizumab, post-progression therapy.
Ключевые слова: метастатический колоректальный рак, бевацизумаб, терапия после прогрессирования.
________________________________________________
Key words: metastatic colorectal cancer, bevacizumab, post-progression therapy.
Полный текст
Список литературы
1. Schmoll HJ, Van Cutsem E, Stein A et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23 (10): 2479–516.
2. Adams RA, Meade AM, Seymour MT et al. Intermittent vs continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011; 12 (7): 642–53.
3. Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377 (9783): 2103–14.
4. Tveit K, Guren T, Glimelius B et al. Randomized phase III study of 5-flurouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line therapy of metastatic colorectal cancer: the NORDIC VII study (NCT0014314), by the Nordic Colorectal Cancer Biomodulation Group. J Clin Oncol 2011; 29 (Suppl. 4): abstr. 365.
5. Saltz LB, Clarke S, Diaz-Rubio E at al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). 2007 GI Cancers Symposium. Abstr. 238.
6. Kabbinavar F, Hurwitz HL, Fehrenbacher L et al. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60–5.
7. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697–705.
8. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42.
9. Rosen O, Yi J, Hurwitz HI et al. Clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Ann Oncol 2008; 19 (Suppl. 6): 19. Abstr. 0-035.
10. Hurwitz HI, Yi J, Ince W et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncol 2009; 14 (1): 22–8.
11. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer. A randomized phase III study. JCO 2008; 26: 2012–9.
12. Cassidy J, Clarke S, Díaz-Rubio E et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011; 105 (1): 58–64.
13. Miles D, Harbeck N et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011; 29 (1): 83–8.
14. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin stop-and-go fashion in advanced colorectal cancer – a GERCOR study. JCO 2006; 24: 394–400.
15. Chibaudel B, Maindrault-Goebel F, Lledo G et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. JCO 2009; 27: 5727–33.
16. Perez-Staub N, Chibaudel B, Figer A et al. Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer? A GERCOR study. J Clin Oncol 2008; 26 (Suppl.): 4037.
17. Tabernero J, Aranda E, Gomez A et al. Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus bevacizumab or singl-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC). The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors, TTD). JCO 2010; 28 (Suppl. 15): 3501.
18. Diaz-Rubio E, Gomaz-Espana A, Massuti B et al. First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer. The Phase III MACRO. Oncolog 2012; 17: 15–25.
19. Grothey A, Hart LL, Rowland KM et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC). Final results of the phase III CONcePT trial. JCO 2008; 26 (Suppl. 15): 4010.
20. Koopman M, Simkens L HJ, Ten Tije AJ et al. Maintenance treatment with capecitabine and bevacizumab vs observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). ASCO 2013; J Clin Oncol 2013; 31 (Suppl.). Abstr. 3502.
21. Koeberle D, Betticher DC, Von Moos R et al. Bevacizumab continuation vs no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer. A randomized phase III noninferiority trial (SAKK 41/06). ASCO 2013. J Clin Oncol 2013; 31 (Suppl.). Abstr. 3503.
22. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer. Results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326–34.
23. Cohn AL, Bekaii-Saab T, Bendell JC et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC). Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). J Clin Oncol 2010; 28 (Suppl. 15): 3596.
24. Arnold D, Andre T, Bennouna J et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: results of randomized phase III intergroup study. J Clin Oncol 2012; 30 (Suppl. 15). Abstr. CRA 3503.
25. Masi G, Loupakis F, Salvatore L et al. A randomized phase III study evaluating the continuation of bevacizumab (BV) beyond progression in metastatic colorectal cancer (mCRC) patients (pts) who received BV as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord Ovest (GONO). ESMO 2012; Ann Oncol 2012; 23 (Suppl. 9): Abstr. LBA17.
26. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer, previously treated with an oxaliplatin-based regimen. Ann Oncol 2012; 30 (28): 3499–506.
27. Van Cutsem E, Tabernero J, Lakomy R et al. Intravenous (IV) aflibercept vs placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC10262–VELOUR). Ann Oncol 2011; 22 (Suppl. 5): 10–8.
28. Allegra CJ, Lacomy R, Tabernero J et al. Effects of prior bevacizumab (B) use on outcomes from the VELOUR study. A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. ASCO 2012; J Clin Oncol 2012; 30 (Suppl. 15). Abstr. 3505.
29. Cohn AL, Hecht JR, Dakhil S et al. SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC). J Clin Oncol 2013; 31 (Suppl.). Abstr. 3616.
2. Adams RA, Meade AM, Seymour MT et al. Intermittent vs continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011; 12 (7): 642–53.
3. Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377 (9783): 2103–14.
4. Tveit K, Guren T, Glimelius B et al. Randomized phase III study of 5-flurouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line therapy of metastatic colorectal cancer: the NORDIC VII study (NCT0014314), by the Nordic Colorectal Cancer Biomodulation Group. J Clin Oncol 2011; 29 (Suppl. 4): abstr. 365.
5. Saltz LB, Clarke S, Diaz-Rubio E at al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). 2007 GI Cancers Symposium. Abstr. 238.
6. Kabbinavar F, Hurwitz HL, Fehrenbacher L et al. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60–5.
7. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697–705.
8. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42.
9. Rosen O, Yi J, Hurwitz HI et al. Clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Ann Oncol 2008; 19 (Suppl. 6): 19. Abstr. 0-035.
10. Hurwitz HI, Yi J, Ince W et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncol 2009; 14 (1): 22–8.
11. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer. A randomized phase III study. JCO 2008; 26: 2012–9.
12. Cassidy J, Clarke S, Díaz-Rubio E et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011; 105 (1): 58–64.
13. Miles D, Harbeck N et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011; 29 (1): 83–8.
14. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin stop-and-go fashion in advanced colorectal cancer – a GERCOR study. JCO 2006; 24: 394–400.
15. Chibaudel B, Maindrault-Goebel F, Lledo G et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. JCO 2009; 27: 5727–33.
16. Perez-Staub N, Chibaudel B, Figer A et al. Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer? A GERCOR study. J Clin Oncol 2008; 26 (Suppl.): 4037.
17. Tabernero J, Aranda E, Gomez A et al. Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus bevacizumab or singl-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC). The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors, TTD). JCO 2010; 28 (Suppl. 15): 3501.
18. Diaz-Rubio E, Gomaz-Espana A, Massuti B et al. First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer. The Phase III MACRO. Oncolog 2012; 17: 15–25.
19. Grothey A, Hart LL, Rowland KM et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC). Final results of the phase III CONcePT trial. JCO 2008; 26 (Suppl. 15): 4010.
20. Koopman M, Simkens L HJ, Ten Tije AJ et al. Maintenance treatment with capecitabine and bevacizumab vs observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). ASCO 2013; J Clin Oncol 2013; 31 (Suppl.). Abstr. 3502.
21. Koeberle D, Betticher DC, Von Moos R et al. Bevacizumab continuation vs no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer. A randomized phase III noninferiority trial (SAKK 41/06). ASCO 2013. J Clin Oncol 2013; 31 (Suppl.). Abstr. 3503.
22. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer. Results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326–34.
23. Cohn AL, Bekaii-Saab T, Bendell JC et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC). Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). J Clin Oncol 2010; 28 (Suppl. 15): 3596.
24. Arnold D, Andre T, Bennouna J et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: results of randomized phase III intergroup study. J Clin Oncol 2012; 30 (Suppl. 15). Abstr. CRA 3503.
25. Masi G, Loupakis F, Salvatore L et al. A randomized phase III study evaluating the continuation of bevacizumab (BV) beyond progression in metastatic colorectal cancer (mCRC) patients (pts) who received BV as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord Ovest (GONO). ESMO 2012; Ann Oncol 2012; 23 (Suppl. 9): Abstr. LBA17.
26. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer, previously treated with an oxaliplatin-based regimen. Ann Oncol 2012; 30 (28): 3499–506.
27. Van Cutsem E, Tabernero J, Lakomy R et al. Intravenous (IV) aflibercept vs placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC10262–VELOUR). Ann Oncol 2011; 22 (Suppl. 5): 10–8.
28. Allegra CJ, Lacomy R, Tabernero J et al. Effects of prior bevacizumab (B) use on outcomes from the VELOUR study. A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. ASCO 2012; J Clin Oncol 2012; 30 (Suppl. 15). Abstr. 3505.
29. Cohn AL, Hecht JR, Dakhil S et al. SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC). J Clin Oncol 2013; 31 (Suppl.). Abstr. 3616.
Авторы
Е.В.Артамонова
ФГБУ РОНЦ им. Н.Н.Блохина РАМН, Москва
ФГБУ РОНЦ им. Н.Н.Блохина РАМН, Москва
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.